Implications of Part D for mentally Ill dual eligibles: A challenge for medicare

Health Affairs

Volumn 25, Issue 2, 2006, Pages 491-500

  Morden, Nancy E ^a   Garrison Jr , Louis P ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

COST; ECONOMICS; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; INSURANCE; MEDICAID; MEDICARE; MENTAL DISEASE; NURSING HOME; ORGANIZATION AND MANAGEMENT; PUBLICATION; REVIEW; UNITED STATES;

COST SHARING; ELIGIBILITY DETERMINATION; FORMULARIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE SELECTION BIAS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; MEDICARE; MENTAL DISORDERS; NURSING HOMES; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 33645677383     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.2.491     Document Type: Review

References (59)

1. S.H. Zuvekas, "Prescription Drugs and the Changing Patterns of Treatment for Mental Disorders, 1996-2001," Health Affairs 24, no. 1 (2005): 195-205.
2. Centers for Medicare and Medicaid Services, A Strategy for Transitioning Dual Eligibles from Medicaid to Medicare Prescription Drug Coverage, May 2005, http://new.cms.hhs.gov/States/Downloads/strategyfortransitioningDE.pdf (accessed 18 January 2006).
3. J. Kasper, R. Elias, and B. Lyons, Dual Eligibles: Medicaid's Role in Filling Medicare's Gaps, March 2004, http://www.kff.org/medicaid/7058.cfm (accessed 21 December 2005).
4. J. Kasper, R. Elias, and B. Lyons, Dual Eligibles: Medicaid's Role in Filling Medicare's Gaps, 2004, http://www.kff.org/medicaid/7058.cfm Ibid.;
5. and B. Bruen and J. Holahan, Shifting the Cost of Dual Eligibles: Implications for States and the Federal Government, November 200.3, http://www.kff.org/medicaid/4152.cfm (accessed 21 December 2005).
6. B. Stuart, L. Simoni-Wastila, and D. Chauncey, "Assessing the Impact of Coverage Gaps in the Medicare Part D Drug Benefit," Health Affairs 24 (2005): w167-w179 (published online 19 April 2005; 10.1377/hlthaff.w5.167).
7. Kaiser Commission on Medicaid and the Uninsured, "Dual Eligibles: Medicaid's Role for Low-Income Medicare Beneficiaries," January 2005, http://www.kff.org/medicaid/4091-03.cfm (accessed 21 December 2005).
8. Kasper et al., Dual Eligibles.
9. U.S. Centers for Disease Control and Prevention, "Data Warehouse on Trends in Health and Aging," April 2005, http://www.cdc.gov/nchs/agingact. htm (accessed 20 April 2005);
10. and N.A. Krauss and B.M. Altman, Characteristics of "Nursing Home Residents - 1996, MEPS Research Findings no. 5, May 2001, http://www.meps.ahrq. gov/papers/rf5_99-0006/rf5.htm (accessed 29 April 2005).
11. Krauss and Altman, Characteristics of Nursing Home Residents;
12. and J.P. Hall, J.M. Moore, and T.I. Shireman, Unintended Consequences: The Potential Impact of Medicare Part D on Dual Eligibles with Disabilities in Medicaid Work Incentive Programs, June 2005, http://www.kff.org/medicaid/7330. cfm (accessed 18 August 2005).
13. Kasper et al., Dual Eligibles.
14. D. Mendelson et al., "Prescription Drugs in Nursing Homes: Managing Costs and Quality in a Complex Environment," Issue Brief no. 784, November 2002, http://www.nhpf.org/index.cfm?fuseaction-Details& key-439 (accessed 6 December 2005);
15. and D.G. Safran et al., "Prescription Drug Coverage and Seniors: Findings from a 2003 National Survey," Health Affairs 24 (2005): w152-w166 (published online 19 April 2005; 10.1377/hlthaff.w5.152).
16. C. Koyanagi, S. Forquer, and E. Alfano, "MedicaidPolicies to Contain Psychiatric Drug Costs," Health Affairs 24, no. 2 (2005): 536-544.
17. J.S. Crowley, D. Ashner, and L. Elam, Medicaid Outpatient Prescriptian Drug Benefits: Findings from a National Survey, 2003, December 2003, http://www.kff.org/medicaid/4164.cfm (accessed 21 December 2005).
18. T.L. Mark et al., "U.S. Spending for Mental Health and Substance Abuse Treatment, 1991-2001," Health Affairs 24 (2005): w133-w142 (published online 29 March 2005; 10.1377/hlthaff.w5.133);
19. and B. Bruen and A. Ghosh, Medicaid Prescription Drug Spending and Use, June 2004, http://www.kff.org/medicaid/7111a.cfm (accessed 22 December 2005).
20. S. Heffler et al., "U.S. Health Spending Projections for 2004-2014," Health Affairs 24 (2005): w74-w85 (published online 23 February 2005; 10.1377/hlthaff.w5.74).
21. M. Olfson et al., "National Trends in the Outpatient Treatment of Depression," Journal of the American Medical Association 287, no. 2 (2002): 203-209;
22. and Zuvekas, "Prescription Drugs."
23. National Institute for Health Care Management Research and Education Foundation, Prescription Drug Expenditures in 2001: Another Year of Escalating Costs, 6 May 2002, http://www.nihcm.org/spending2001.pdf (accessed 6 December 2005).
24. I.D. Glick et al., "Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia," Annals of Internal Medicine 134, no. 1 (2001): 47-60;
25. and H.A. Huskamp, "Managing Psychotropic Drug Costs: Will Formularies Work?" Health Affairs 22, no. 5 (2003): 84-96.
26. S.B. Soumerai et al., "Effects of a limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia," New England Journal of Medicine 331, no. 10 (1994): 650-655.
27. CMS, "Medicare Modernization Act Final Guidelines - Formularies," April 2005, http://new.cms.hhs.gov/PrescriptionDrugCovContra/ Downloads/FormularyGuidance.pdf (accessed 18 January 2006).
28. CMS, "Find Answers," http://questions.cms.hhs.gov/cgi-bin/ cmshhs.cfg/php/enduser/std_alp.php?p_sid=shZ*FZZh (search for question ID no. 4923, "Why is CMS requiring 'all or substantially all' of the drugs in the antidepressant, antipsychotic, anticonvulsant, anticancer, immunosuppressant and HIV/AIDS categories?") (accessed 23 January 2006).
29. L. Dixon et al., "The Association of Medical Comorbidity in Schizophrenia with Poor Physical and Mental Health," Journal of Nervous and Mental Disease 187, no. 8 (1999): 496-502.
30. J.M. Donohue, "Formulary Design in the New Medicare Drug Benefit: Incentives for Drug Plans and Implications for Mental Health Treatment and Spending" (Working paper presented at the Third NIMH Pharmacoeconomics Workshop: MMA03 and Psychotropic Medication, Bethesda, Maryland, 23 May 2005).
31. CMS, "Medicare Modernization Act Final Guidelines."
32. J. Hoadley, The Effect of Formularies and Other Cost Management Tools on Access to Medications: An Analysis of the MMA and the Final Rule, March 2005, http://www.kff.org/medicare/7299.cfm (accessed 22 December 2005).
33. For a detailed discussion of adverse selection, see M.V. Pauly and Y. Zeng, "Adverse Selection and the Challenges to Stand-Alone Prescription Drug Insurance," Frontiers in Health Policy Research 7 (2004): 55-74.
34. CMS, A Strategy for Transitioning Dual Eligibles.
35. CMS, "Medicare Program; Medicare Prescription Drug Benefit; Final Rule," 28 January 2005, http://a257.g.akamaitech.net/7/257/2422/ 01jan20051800/edocket.access.gpo.gov/2005/05-1321.htm (accessed 5 May 2005).
36. J. Avorn and J.H. Gurwitz, "Drug Use in the Nursing Home," Annals of Internal Medicine 123, no. 3 (1995): 195-204.
37. E.E. Fortess et al., "Utilization of Essential Medications by Vulnerable Older People after a Drug Benefit Cap: Importance of Mental Disorders, Chronic Pain, and Practice Setting," Journal of the American Geriatrics Society 49, no. 6 (2001): 793-797;
38. and R. Tamblyn et al, "Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons," Journal of the American Medical Association 285, no. 4 (2001): 421-429.
39. CMS, "Medicare Program; Medicare Prescription Drug Benefit."
40. L. Schofield, "The Impact on States of the Medicare Drug Benefit: Information for State Legislators," April 2005, http://www.npcnow.org/ newsroorn/documents/Medicare-LegislatorsFINAL.pdf (accessed 9 September 2005).
41. J. Eichner and B.C. Vladeck, "Medicare as a Catalyst for Reducing Health Disparities," Health Affairs 24, no. 2 (2005): 365-375.
42. M. Lillie-Blanton, O.E. Rushing, and S. Ruiz, Key Facts: Race, Ethnicity, and Medical Care, June 2003, http://www.kff.org/minorityhealth/6069-index.cfm (accessed 10 January 2006).
43. Zuvekas, "Prescription Drugs";
44. and Olfson et al., "National Trends."
45. M. Duggan, "Do New Prescription Drugs Pay for Themselves? The Case of Second-Generation Antipsychotics," Journal of Health Economics 24, no. 1 (2005): 1-31.
46. R.G. Frank, R.M. Conti, and H.H. Goldman, "Mental Health Policy and Psychotropic Drugs," Milbank Quarterly 83, no. 2 (2005): 271-298.
47. CMS, "Testimony of Dennis Smith, Director, Center for Medicaid and State Operations, Centers for Medicare and Medicaid Services, on Medicaid Prescription Drug Reimbursement Before the House Energy and Commerce Subcommittee on Oversight and Investigations," 7 December 2004, http://www.cms.hhs.gov/media/press/testimony.asp?Counter-1278 (accessed 10 September 2005).
48. 8. Bruen and Ghosh, Medicaid Prescription Drug Spending and Use.
49. Frank et al., "Mental Health Policy."
50. J.R. Geddes et al., "Selective Serotonin Reuptake Inhibitors (SSRIs) versus Other Antidepressants for Depression," Cochrane Database of Systematic Reviews 1999, Issue 4 (1999), http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD001851/frame.html (accessed 20 April 2005);
51. S. Leucht et al., "Efficacy and Extrapyramidal Side-Effects of the New Antipsychotics Olanzapine, Quetiapine, Risperidone, and Sertindole Compared to Conventional Antipsychotics and Placebo: A Meta-Analysis of Randomized Controlled Trials," Schizophrenia Research 35, no. 1 (1999): 51-68;
52. and G.E. Simon et al., "Long-Term Outcomes of Initial Antidepressant Drug Choice in a 'Real World' Randomized. Trial," Archives of Family Medicine 8, no. 4 (1999): 319-325.
53. J.A. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no. 12 (2005): 1209-1223.
54. B.A. Briesacher et al., "The Quality of Antipsychotic Drug Prescribing in Nursing Homes," Archives of Internal Medicine 165, no. 11 (2005): 1280-1285.
55. I.D. Glick et al., "Treatment with Atypical Antipsychotics: New Indications and New Populations," Journal of Psychiatric Research 35, no. 3 (2001): 187-191;
56. and P.E. Lee et al., "Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review," British Medical Journal 329, no. 7457 (2004): 75-79.
57. L.S. Schneider, K.S. Dagerman, and P. Insel, "Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia: Meta-Analysis of Randomized Placebo-controlled Trials," Journal of the American Medical Association 294, no. 15 (2005): 1934-1943.
58. Donohue, "Formulary Design."
59. P.V. Rabins and C.G. Lyketsos, "Antipsychotic Drugs in Dementia: What Should Be Made of the Risks?" Journal of the American Medical Association 294, no. 15 (2005): 1963-1965.